TY - JOUR
T1 - Second primary malignancies in patients with male breast cancer
AU - Hemminki, K.
AU - Scélo, G.
AU - Boffetta, P.
AU - Mellemkjaer, L.
AU - Tracey, E.
AU - Andersen, A.
AU - Brewster, D. H.
AU - Pukkala, E.
AU - McBride, M.
AU - Kliewer, E. V.
AU - Chia, K. S.
AU - Pompe-Kirn, V.
AU - Martos, C.
AU - Jonasson, J. G.
AU - Li, X.
AU - Brennan, P.
N1 - Funding Information:
We acknowledge the work of Didier Colin, IARC, for initial preparation of the data set. The analysis was supported by a R03 grant to IARC by the US NCI.
PY - 2005/4/11
Y1 - 2005/4/11
N2 - An international multicentre study of first and second primary neoplasms associated with male breast cancer was carried out by pooling data from 13 cancer registries. Among a total of 3409 men with primary breast cancer, 426 (12.5%) developed a second neoplasia; other than breast cancer, a 34% overall excess risk of second primary neoplasia, affecting the small intestine (standardised incidence ratio, 4.95, 95% confidence interval, 1.35- 12.7), rectum (1.78, 1.20-2.54), pancreas (1.93, 1.14-3.05), skin (nonmelanoma, 1.65, 1.16-2.29), prostate (1.61, 1.34-1.93) and lymphohaematopoietic system (1.63, 1.12-2.29). A total of 225 male breast cancers was recorded after cancers other than breast cancer, but an increase was found only after lymphohaematopoietic neoplasms. BRCA2 (and to some extent BRCA1) mutations may explain the findings for pancreatic and prostate cancers. Increases at other sites may be related to unknown factors or to chance. This large study shows that the risks for second discordant tumours after male breast cancer pose only a moderate excess risk.
AB - An international multicentre study of first and second primary neoplasms associated with male breast cancer was carried out by pooling data from 13 cancer registries. Among a total of 3409 men with primary breast cancer, 426 (12.5%) developed a second neoplasia; other than breast cancer, a 34% overall excess risk of second primary neoplasia, affecting the small intestine (standardised incidence ratio, 4.95, 95% confidence interval, 1.35- 12.7), rectum (1.78, 1.20-2.54), pancreas (1.93, 1.14-3.05), skin (nonmelanoma, 1.65, 1.16-2.29), prostate (1.61, 1.34-1.93) and lymphohaematopoietic system (1.63, 1.12-2.29). A total of 225 male breast cancers was recorded after cancers other than breast cancer, but an increase was found only after lymphohaematopoietic neoplasms. BRCA2 (and to some extent BRCA1) mutations may explain the findings for pancreatic and prostate cancers. Increases at other sites may be related to unknown factors or to chance. This large study shows that the risks for second discordant tumours after male breast cancer pose only a moderate excess risk.
KW - BRCA in men
KW - Cancer registry
KW - Discordant sites
KW - Pooled analysis
KW - Subsequent malignancy
UR - http://www.scopus.com/inward/record.url?scp=20944443183&partnerID=8YFLogxK
U2 - 10.1038/sj.bjc.6602505
DO - 10.1038/sj.bjc.6602505
M3 - Article
C2 - 15798766
AN - SCOPUS:20944443183
SN - 0007-0920
VL - 92
SP - 1288
EP - 1292
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 7
ER -